Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

GeneCards

A widely-accessed searchable, integrated, database of all known and predicted human genes, with transcriptomic, genetic, proteomic, functional and disease information.

Visit GeneCards

MalaCards

An integrated annotated database of human diseases, modeled on the architecture and richness of the popular GeneCards database of human genes.

Visit MalaCards

Bookmark/Print/Share

Home » Drug Information

STUDY VOLUNTEER SURVEY

Have you participated in a clinical trial?

CenterWatch is conducting a survey of study volunteers to learn more about participants' experiences. If you have participated in a study, please complete our short survey.

TAKE THE SURVEY

Do you live in constant pain? Find clinical trials for pain.

Search Our Drug Database FREE For 5 days!

Access detailed profiles on more than 4,000 new drug therapies in active clinical trials worldwide.

Request a demo


View By:YearCompanyConditionsTherapeutic AreasDrug Names

20142013201220112010200920082007200620052004200320022001200019991998199719961995

FDA Approved Drugs

The following database contains a listing of drugs approved by the Food and Drug Administration (FDA) for sale in the United States. Drug information typically includes the drug name, approval status, indication of use, and clinical trial results. Review descriptions for our medical therapeutic area list to help assist in your search.

Join our Drug Research Updates group on LinkedIn! 

Find out more about the types of drugs included in this listing.

2014

Endocrinology

Aveed (testosterone undecanoate) injection; Endo Pharmaceuticals; For the treatmenr of hypogonadism, Approved March 2014

Farxiga (dapagliflozin); Bristol-Myers Squibb; For the treatment of type II diabetes, January of 2014

Family Medicine

Aveed (testosterone undecanoate) injection; Endo Pharmaceuticals; For the treatmenr of hypogonadism, Approved March 2014

Farxiga (dapagliflozin); Bristol-Myers Squibb; For the treatment of type II diabetes, January of 2014

Myalept (metreleptin for injection); Bristol-Myers Squibb; For the treatment of congenital or acquired generalized lipodystrophy, Approved February of 2014

Northera (droxidopa); Chelsea Therapeutics; For the treatment of neurogenic orthostatic hypotension, Approved February 2014

Qudexy XR (topiramate); Upsher-Smith Laboratories; For the treatment of partial onset and primary generalized tonic-clonic seizures and Lennox-Gastaut Syndrome, Approved March 2014

Tivorbex (indomethacin); Iroko Pharmaceuticals; For the treatment of acute pain, Approved February of 2014

Xartemis XR (oxycodone hydrochloride and acetaminophen) extended release; Mallinckrodt Pharmaceuticals; For the management of acute pain, Approved March 2014

Genetic Disease

Qudexy XR (topiramate); Upsher-Smith Laboratories; For the treatment of partial onset and primary generalized tonic-clonic seizures and Lennox-Gastaut Syndrome, Approved March 2014

Vimizim (elosulfase alfa); BioMarin; For the treatment of Mucopolysaccharidosis type IVA, Approved February 2014

Hematology

Imbruvica (ibrutinib); Pharmacyclics; For the treatment of chronic lymphocytic leukemia, Approved February 2014

Immunology

Myalept (metreleptin for injection); Bristol-Myers Squibb; For the treatment of congenital or acquired generalized lipodystrophy, Approved February of 2014

Infections and Infectious Diseases

Impavido (miltefosine); Knight Therapeutics; For the treatment of visceral, cutaneous and mucosal leishmaniasis, Approved March 2014

Musculoskeletal

Vimizim (elosulfase alfa); BioMarin; For the treatment of Mucopolysaccharidosis type IVA, Approved February 2014

Neurology

Hetlioz (tasimelteon); Vanda Pharmaceuticals; For the treatment of non-24-hour sleep-wake disorder in the totally blind, January 2014

Northera (droxidopa); Chelsea Therapeutics; For the treatment of neurogenic orthostatic hypotension, Approved February 2014

Qudexy XR (topiramate); Upsher-Smith Laboratories; For the treatment of partial onset and primary generalized tonic-clonic seizures and Lennox-Gastaut Syndrome, Approved March 2014

Tivorbex (indomethacin); Iroko Pharmaceuticals; For the treatment of acute pain, Approved February of 2014

Xartemis XR (oxycodone hydrochloride and acetaminophen) extended release; Mallinckrodt Pharmaceuticals; For the management of acute pain, Approved March 2014

Oncology

Imbruvica (ibrutinib); Pharmacyclics; For the treatment of chronic lymphocytic leukemia, Approved February 2014

Ophthalmology

Hetlioz (tasimelteon); Vanda Pharmaceuticals; For the treatment of non-24-hour sleep-wake disorder in the totally blind, January 2014

Pediatrics/Neonatology

Qudexy XR (topiramate); Upsher-Smith Laboratories; For the treatment of partial onset and primary generalized tonic-clonic seizures and Lennox-Gastaut Syndrome, Approved March 2014

Vimizim (elosulfase alfa); BioMarin; For the treatment of Mucopolysaccharidosis type IVA, Approved February 2014

Pharmacology/Toxicology

Myalept (metreleptin for injection); Bristol-Myers Squibb; For the treatment of congenital or acquired generalized lipodystrophy, Approved February of 2014

Sleep

Hetlioz (tasimelteon); Vanda Pharmaceuticals; For the treatment of non-24-hour sleep-wake disorder in the totally blind, January 2014